Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Total Liabilities: 2022-2024

Historic Total Liabilities for Taysha Gene Therapies (TSHA) over the last 3 years, with Dec 2024 value amounting to $88.8 million.

  • Taysha Gene Therapies' Total Liabilities rose 6.72% to $97.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $97.6 million, marking a year-over-year increase of 6.72%. This contributed to the annual value of $88.8 million for FY2024, which is 9.16% down from last year.
  • As of FY2024, Taysha Gene Therapies' Total Liabilities stood at $88.8 million, which was down 9.16% from $97.8 million recorded in FY2023.
  • Taysha Gene Therapies' 5-year Total Liabilities high stood at $125.3 million for FY2022, and its period low was $88.8 million during FY2024.
  • In the last 3 years, Taysha Gene Therapies' Total Liabilities had a median value of $97.8 million in 2023 and averaged $104.0 million.
  • Data for Taysha Gene Therapies' Total Liabilities shows a maximum YoY fell of 21.97% (in 2023) over the last 5 years.
  • Taysha Gene Therapies' Total Liabilities (Yearly) stood at $125.3 million in 2022, then decreased by 21.97% to $97.8 million in 2023, then decreased by 9.16% to $88.8 million in 2024.